Introduction
Thanks to its striking effectiveness, imatinib (IM) (Glivec, Gleevec; Novartis Pharmaceuticals, NJ), a Bcr-Abl tyrosine kinase inhibitor (TKI), has rapidly become the standard frontline treatment of Philadelphia positive (Ph-pos) Chronic Myeloid Leukemia (CML).
1,2 However, about 5% of the patients must discontinue imatinib due to adverse events (AEs) and about 20% of the patients fail to respond adequately, according to the European LeukemiaNet criteria. 3 In CML patients resistant or intolerant to imatinib, alternative treatments are needed. Nilotinib (Tasigna®, formerly AMN107; Novartis Pharmaceuticals, NJ) is an oral aminophenylpyrimidine derivative that has been rationally designed to be more selective against the Bcr-Abl tyrosine kinase than imatinib. The higher selectivity results in a superior potency against imatinib-resistant cell lines, including most of the cell lines which bear mutations, and also in a lower incidence of adverse events. 4, 5 Nilotinib has proved to be effective and safe in large studies involving patients with imatinib-resistant and/or intolerant CML; however, a significant (up to 18%) incidence of grade 3-4 pancreatic enzymes elevation has been reported. [6] [7] [8] Enzyme increase was not associated to acute pancreatitis in the great majority of cases; nonetheless, no data have yet been reported which describe the behaviour of pancreatic enzymes over time and the clinical relevance of these laboratory alterations. For this purpose, we report our experience with 37 imatinib-resistant or intolerant CML patients who were treated with Nilotinib.
Design and Methods
Patients were enrolled between June 2005 and February 2008 in two studies sponsored by Novartis Pharmaceuticals (registered at www.clinicaltrials.gov under NCT00384228 and NCT00302016). The studies were conducted in accordance with the Declaration of Helsinki. Both studies were approved by the ethic committee of the St. Orsola-Malpighi University Hospital and all patients gave written informed consent according to institutional guidelines. Enrolment criteria have been described elsewhere. 6 Briefly, patients with imatinibresistant or intolerant CML in chronic phase, accelerated phase and blast crisis who were at least 18 years old were eligible if they had adequate performance status (World Health Organization Performance Score ≤2), and normal hepatic, renal, and cardiac functions. Nilotinib starting dose was 400 mg twice daily for all patients. Blood counts and bio-An increase in the serum concentration of pancreatic enzymes (amylase and lipase) was reported in a proportion of imatinib-resistant and/or intolerant Philadelphia-positive chronic myeloid leukemia (CML) patients treated with nilotinib. Acute pancreatitis was very rare, and the relevance of these laboratory alterations remains unknown. We report on 8 CML patients who developed serum lipase/amylase elevation during treatment with Nilotinib. After a median follow-up of 26 months, none of these patients developed an acute pancreatitis or clinical signs of pancreatic disease. Pancreatic hyperenzymemia never led to permanent drug discontinuation and required Nilotinib temporary interruption in one case only. The median cumulative duration of dose interruptions and response to treatment were comparable in patients with or without pancreatic enzyme elevation. The mechanisms of action of chemistries were obtained weekly for the first 8 weeks, and thereafter every 2 weeks. Cytogenetic studies on bone marrow samples were performed with conventional cytogenetic analysis at baseline and at 3-6 month intervals thereafter. The cytogenetic response was rated according to European LeukemiaNet guidelines.
3 Safety assessments included evaluation of adverse events, hematologic and biochemical testing, urinalysis, cardiac enzyme assessment, serial electrocardiogram evaluation, and physical examination. Amylase and lipase concentrations were measured at the central laboratory of our hospital. The normal reference range is 20-110 IU/L for amylase and 13-55 IU/L for lipase. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0.
Results
Patients A total of 37 CML patients intolerant or resistant to imatinib were enrolled in the studies. Nineteen were male and 18 female. Median age at CML diagnosis was 49 years (range, 12-71); median interval between CML diagnosis and nilotinib start was 48 months (range, 4-266). Twenty-four patients were in chronic phase, 4 in accelerated phase and 9 in blast phase (4 lymphoid and 5 myeloid blast phase). Nilotinib was initiated because of imatinib-resistance in 30 patients (81%). In the remaining 7 imatinib-intolerant patients, reasons for imatinib discontinuation were: fluid retention (4 patients), skin reactions (1), hematological toxicity (2). Median follow-up of living patients was 29 months (range, 9-42).
Incidence and severity of pancreatic enzymes elevations
Lipase and amylase serum levels have been performed in all patients every 1 to 3 months, according to protocol's requirements and to medical indications, during the entire course of nilotinib therapy. Serum fasting glucose levels were normal and no signs of malabsorption were ever recorded. Therefore, pancreatic function tests were neither required nor performed. During the course of nilotinib therapy, 8 patients (21.6%) showed increased lipase and/or amylase levels ( Table 2 ). Seven patients were in chronic phase and one in accelerated phase. Median age at nilotinib start was 51 years (range, 36-68); 6 were male and 2 female. The median interval between Nilotinib start and lipase/amylase elevation was 3 months (range, 7 days-30 months). Lipase elevation was detected as single alteration in 5 patients, while a transient amylase elevation was concomitantly detected in two patients. One patient experienced isolated serum amylase elevation grade 2. Overall, in 5 cases (13.5%) serum lipase increase was grade 3 (from 2 to 5 times over the upper normal limit), whereas all amylase elevations were grade 2 (from 1.5 to 2 times over the upper normal limit). Pancreatic enzymes increase presented as single isolated elevated values or as transient episodes in all cases, with the exception of patient MB, who experienced frequent recurrences of hyperenzymemia. During treatment, all patients had 
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maintained the same lifestyle and alimentary habits; in particular, alcohol abuse was excluded in all cases. Concomitant drugs were also recorded ( Table 2 ), but none of them seemed to be related to pancreatic hyperenzymemia.
Clinical implications of pancreatic enzymes elevations
In all these subjects, the hyperenzymemia was discovered incidentally when tests for pancreatic enzymes were carried out as a part of a routine work-up. None of these patients was diabetic, nor presented a history positive for gastrointestinal diseases, including gallstones, bile ducts occlusions, pancreatitis, hepatitis. At the first evidence of enzyme elevation, all patients were studied with abdominal ultrasonography, which resulted normal in all cases. Other concomitant AEs were recorded and are listed in Table 1 . Impaired renal function was also excluded. None of the patients developed acute pancreatitis. Patient MB presented a serum lipase increase grade 3 at baseline evaluation; an abdominal computed tomography (CT) excluded pancreatic pathoanatomic anomalies before Nilotinib start. In this patient, pancreatic enzymes showed a fluctuating behaviour; the phenomenon was monitored with a 15-days clinic and laboratory tests, and was investigated with 3 computed tomography scan and 1 MRCP (magnetic resonance colangio-pancreatography), all of which failed to reveal abdominal anatomic alterations. Endoscopic retrograde pancreatography9 and exocrine pancreatic function study by the secretin-cerulein test10 were not performed because potentially hurtful, in absence of clinical signs of pancreatic disease. At last follow-up, 42 months after Nilotinib start, the patient is alive and well, in continuous, Nilotinib-induced complete cytogenetic response, and in ongoing therapy with Nilotinib at reduced dosage (400 mg daily) (Figure 1) .
Overall, Nilotinib dose was reduced to 400 mg daily in four patients, because of pancreatic hyperenzymemia (patients MB and MG), recurrent thrombocytopenia (patient PG) and gastric intolerance (patient PD). Only patient MG discontinued Nilotinib for 26 days because of hyperenzymemia; the median cumulative duration in days of dose interruptions was similar in CP-CML patients with or without pancreatic enzyme elevations (19 days, range 0-50, versus 1 days, range 0-146, respectively, p=0.23). The proportion of complete cytogenetic responders was also comparable in the two groups: among the 7 CP-CML patients with pancreatic hyperenzymemia, 6 achieved a complete cytogenetic response (versus 9 complete responders out of 17 chronic phase patients without enzyme elevation, p=0.19).
Discussion and Results
Pancreatic enzymes elevation was reported as an unexpected adverse event in CML patients treated with nilotinib after imatinib failure. Among the 119 CML patients treated with Nilotinib in accelerated phase, 18% and 2% of the patients experienced a grade 3-4 increase in lipase and amylase levels, respectively, with one patient developing acute pancreatitis after a median duration of treatment of 6.7 months.
7 Grade 3-4 elevation of serum lipase levels was also recorded in 14% of 318 CML patients treated with nilotinib in chronic phase, and acute pancreatitis was reported in 3 cases (1%), with a median duration of exposure of 8 months.
6,8
The reason for pancreatic enzymes elevation is unknown. One mechanism may be due to the capability of nilotinib to inhibit with high affinity the nonreceptor tyrosine kinase c-Abl. Besides the kinase domain, the c-Abl protein interacts with signalling proteins, nucleo-cytoplasmic shuttling, DNA and actin binding sites, thus integrating information from multiple pathways in different cellular compartments.
11
Therefore, it is possible that c-Abl inhibition might interfere with the molecular mechanisms regulating pancreatic cells death, inducing a pancreatic damage. Another possibility is that the drug may act on unknown intracellular pathways involved in Calcium release from the intracellular acinar stores, which regulates exocrine pancreatic secretion, 12, 13 or may promote the accumulation of fatty acid inside the pancreatic acinar cell, which disturbs exocytosis.
14 However, pancreatic enzymes elevations are rarely observed during exposure to other ABL kinase inhibitors, and the molecular mechanisms of action of nilotinib on pancreatic enzymes level deserves to be investigated. However, defining and controlling the clinical implications of the side effects of a new oncology drug is particularly important and challenging, considering the gravity of the disease and the potential therapeutic effect. An increase in serum concentration of pancreatic enzymes is usually an expression of pancreatic disease;
15 however, several conditions can be responsible for elevated amylase and/or lipase levels, which may also be a nonspecific phenomenon without any clinical implication. 16, 17 Particularly, benign pancreatic hyperenzymemia (BPH)
18 is a syndrome characterized by pancreatic enzymes elevations persisting over time with consider- . Regular monitoring and prolonged observation are needed to establish whether pancreatic enzyme elevations during nilotinib therapy are a benign laboratory abnormality or a serious adverse event reflecting a (potential) pancreatic disease. In our experience, with a median observation time longer than 2 years, these alterations were short-lasting and self-limiting, requiring preventative temporary drug discontinuation in one patient only. None of the patients required permanent treatment interruption due to pancreatic enzyme elevation and nilotinib dose was precautionary reduced in two cases only. More importantly, no patient developed acute pancreatitis or clinical signs of pancreatic disease, like pancreatic-type pain, obstructive jaundice, maldigestion, diabetes, pancreatic cysts and ascites. 
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